FGF1<sup>ΔHBS</sup> ameliorates DSS‐induced ulcerative colitis by reducing neutrophil recruitment through the MAPK pathway
This article is part of a themed issue Drugs and Drug Targets in Metabolic and Chronic Inflammatory Diseases. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v182.20/issuetoc.
Authors
- Jianguo Xu (ORCID: https://orcid.org/0000-0003-3649-8229)
- Heng Zheng
- Yong Yang (ORCID: https://orcid.org/0000-0003-1038-9470)
- Linling Wu (ORCID: https://orcid.org/0000-0001-6440-204X)
- Ying Xia (ORCID: https://orcid.org/0000-0002-1437-333X)
- Xianjing Li (ORCID: https://orcid.org/0000-0002-0007-1429)
- Shuang Feng (ORCID: https://orcid.org/0000-0003-4739-2518)
- Qijin Wu
- Shentian Zhuang (ORCID: https://orcid.org/0000-0002-7282-5779)
- Changzhi Zhou (ORCID: https://orcid.org/0000-0002-3965-9561)
- Xinrui Ni
- Yanyan Jin (ORCID: https://orcid.org/0009-0000-6784-6519)
- Yunfei Zhu
- Tong Liang
- Longwei Zhao
Institutions
- China Pharmaceutical University (CN)
- Xuzhou Medical College (CN)
- Wenzhou Medical University (CN)
Publication Details
- Journal
- British Journal of Pharmacology
- Published
- 2025-04-21
- DOI
- https://doi.org/10.1111/bph.70049
- Citations
- 3
- Primary Topic
- Fibroblast Growth Factor Research
- Type
- article
- Field-Weighted Citation Impact
- 2.42
Funders
- National Natural Science Foundation of China